Ads
related to: docetaxel chemotherapy- Common Adverse Reactions
Learn About Managing Potential
Adverse Reactions For ENHERTU®.
- New Approval Info
ENHERTU® Is Now Approved For
a New Indication. Physician Site.
- Efficacy Of ENHERTU®
Learn About The Efficacy
Of ENHERTU® For a New Indication.
- Physician Resources
Access Physician Resources
For ENHERTU® On The Official Site.
- Explore The Data
View More Information On
The Data & Results Of ENHERTU®.
- Prep & Admin
Preparation and Administration
Information For ENHERTU®
- Common Adverse Reactions
Search results
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Benzinga via Yahoo Finance· 8 hours agoOn Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the...
Lung cancer pill outperforms chemotherapy in clinical trials
The Hill via Yahoo News· 2 years agoStory at a glance Lung cancer treatments include immunotherapy, chemotherapy and drugs given orally....
AstraZeneca and Daiichi Sankyo’s ADC improves survival in NSCLC trial
Clinical Trials Arena via Yahoo Finance· 2 days agoAstraZeneca and Daiichi Sankyo have reported high-level overall survival (OS) results from the Phase...
Amgen's Lumakras Cuts Risk Of Progression By 34% In KRAS-Mutated Lung Cancer Patients
Benzinga via Yahoo Finance· 2 years agoAmgen Inc (NASDAQ: AMGN) announced detailed results from the global Phase 3 CodeBreaK 200 trial....
Merck suffers bad week as 3 Keytruda combination trials fail
BioPharma Dive via Yahoo Finance· 6 months agoThe setbacks for Merck demonstrate the challenge drug developers face in improving on Keytruda,...
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
Benzinga via Yahoo Finance· 2 years agoMerck & Co Inc's (NYSE: MRK) Phase 3 KEYNOTE-921 trial of Keytruda combined with chemotherapy...
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
Zacks via Yahoo Finance· 2 years agoGSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with...
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Zacks via Yahoo Finance· 13 hours agoCandel (CADL) surges 431% in the year-to-date period, driven by positive developmental and...
Bristol Myers says KRAS drug succeeds in key trial
BioPharma Dive via Yahoo Finance· 2 months agoConfirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set...
Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall
Benzinga via Yahoo Finance· 1 year agoAileron Therapeutics (NASDAQ: ALRN) announced that a review of initial data from its Phase 1b...
Ads
related to: docetaxel chemotherapy
